PMID- 31584185
OWN - NLM
STAT- MEDLINE
DCOM- 20200219
LR  - 20200219
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
VI  - 146
IP  - 2
DP  - 2020 Jan 15
TI  - Evaluation of Newcastle disease virus mediated dendritic cell activation and 
      cross-priming tumor-specific immune responses ex vivo.
PG  - 531-541
LID - 10.1002/ijc.32694 [doi]
AB  - We have developed an oncolytic Newcastle disease virus (NDV) that has potent in 
      vitro and in vivo anti-tumor activities and attenuated pathogenicity in chickens. 
      In this ex vivo study using the same recombinant NDV backbone with GFP transgene 
      (NDV-GFP, designated as rNDV), we found that rNDV induces maturation of 
      monocyte-derived immature dendritic cells (iDCs) by both direct and indirect 
      mechanisms, which promote development of antigen-specific T cell responses. 
      Addition of rNDV directly to iDCs culture induced DC maturation, as demonstrated 
      by the increased expression of costimulatory and antigen-presenting molecules as 
      well as the production of type I interferons (IFNs). rNDV infection of the HER-2 
      positive human breast cancer cell line (SKBR3) resulted in apoptotic cell death, 
      release of proinflammatory cytokines, and danger-associated molecular pattern 
      molecules (DAMPs) including high-mobility group protein B1 (HMGB1) and heat shock 
      protein 70 (HSP70). Addition of rNDV-infected SKBR3 cells to iDC culture resulted 
      in greatly enhanced upregulation of the maturation markers and release of type I 
      IFNs by DCs than rNDV-infected DCs only. When co-cultured with autologous T 
      cells, DCs pre-treated with rNDV-infected SKBR3 cells cross-primed T cells in an 
      antigen-specific manner. Altogether, our data strongly support the potential of 
      oncolytic NDV as efficient therapeutic agent for cancer treatment.
CI  - (c) 2019 UICC.
FAU - Xu, Qi
AU  - Xu Q
AD  - Microbial Sciences, AstraZeneca Ltd, South San Francisco, CA.
FAU - Rangaswamy, Udaya S
AU  - Rangaswamy US
AD  - Microbial Sciences, AstraZeneca Ltd, South San Francisco, CA.
FAU - Wang, Weijia
AU  - Wang W
AD  - Microbial Sciences, AstraZeneca Ltd, South San Francisco, CA.
FAU - Robbins, Scott H
AU  - Robbins SH
AD  - Microbial Sciences, AstraZeneca Ltd, Gaithersburg, MD.
FAU - Harper, James
AU  - Harper J
AD  - Oncology R&D, AstraZeneca Ltd, Cambridge, United Kingdom.
FAU - Jin, Hong
AU  - Jin H
AD  - Microbial Sciences, AstraZeneca Ltd, South San Francisco, CA.
FAU - Cheng, Xing
AU  - Cheng X
AUID- ORCID: 0000-0002-7611-4763
AD  - Microbial Sciences, AstraZeneca Ltd, South San Francisco, CA.
LA  - eng
PT  - Journal Article
DEP - 20191101
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Interferon Type I)
RN  - 0 (RNA, Viral)
RN  - 0 (RNA, recombinant)
RN  - 63231-63-0 (RNA)
SB  - IM
MH  - Animals
MH  - Chlorocebus aethiops
MH  - Coculture Techniques
MH  - *Cross-Priming
MH  - Dendritic Cells/*immunology/metabolism
MH  - Female
MH  - HeLa Cells
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Interferon Type I/immunology/metabolism
MH  - Neoplasms/immunology/*therapy
MH  - Newcastle disease virus/genetics/immunology
MH  - Oncolytic Virotherapy/*methods
MH  - Oncolytic Viruses/genetics/immunology
MH  - RNA/administration & dosage/genetics
MH  - RNA, Viral/administration & dosage/genetics
MH  - T-Lymphocytes/immunology
MH  - Vero Cells
OTO - NOTNLM
OT  - ex vivo
OT  - Oncolytic Newcastle disease virus
OT  - antitumor immune response
OT  - dendritic cells
EDAT- 2019/10/05 06:00
MHDA- 2020/02/20 06:00
CRDT- 2019/10/05 06:00
PHST- 2019/04/19 00:00 [received]
PHST- 2019/07/03 00:00 [revised]
PHST- 2019/09/05 00:00 [accepted]
PHST- 2019/10/05 06:00 [pubmed]
PHST- 2020/02/20 06:00 [medline]
PHST- 2019/10/05 06:00 [entrez]
AID - 10.1002/ijc.32694 [doi]
PST - ppublish
SO  - Int J Cancer. 2020 Jan 15;146(2):531-541. doi: 10.1002/ijc.32694. Epub 2019 Nov 
      1.